Trinity Biotech (TRIB) said Tuesday it has secured $5.5 million in additional liquidity through amended agreements with Perceptive Advisors, including cash and payment-in-kind interest.
As part of the agreement, Trinity has granted Perceptive 1.5 million additional warrants to buy its American depositary shares and repriced its existing warrants to $0.80 per ADS, Trinity added.
A $5 million deferred payment tied to its acquisition of Waveform Technologies assets was also extended to November 2025, increasing its financial flexibility, Trinity Biotech said.
The liquidity will support the company's transformation plan, including its World Health Organization-approved transition to offshore manufacturing for TrinScreen HIV and Uni-Gold HIV, Trinity Biotech said.
Trinity Biotech were up more than 10% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.